Table 1.
Clinical characteristics of the patients
| Variables | Training Set | External Validation Set | ||||
|---|---|---|---|---|---|---|
| PP (n = 26) | ETP (n = 35) | P | PP (n = 20) | ETP (n = 14) | P | |
| Age, y* | 57.1 ± 10.6 | 58.6 ± 10.6 | 0.89 | 61.3 ± 11.6 | 63.9 ± 12.1 | 0.60 |
| No. of female patients | 10 (38.5%) | 13 (37.1%) | 0.84 | 5 (15.0%) | 4 (28.6%) | 0.07 |
| KPS ≥70 | 21 (80.8%) | 28 (80.0%) | 0.88 | 17 (85.0%) | 11 (78.6%) | 0.36 |
| IDH-wild type | 23 (88.5%) | 34 (97.1%) | 0.21 | 20 (100%) | 14 (100%) | 1 |
| MGMT promoter status (methylated/ unmethylated/NA) | 5/5/16 | 2/12/21 | 0.001 | 12/7/1 | 5/5/5 | 0.02 |
| Surgical extent | 0.09 | 0.81 | ||||
| Biopsy | 0 | 0 | 4 (20.0%) | 3 (21.4%) | ||
| Partial resection | 7 (26.9%) | 13 (37.1%) | 8 (40.0%) | 5 (35.7%) | ||
| Gross total resection | 19 (73.1%) | 22 (62.9%) | 8 (40.0%) | 6 (42.9%) | ||
| Mean time interval between the operation and imaging, days | 103.8 ± 14.4 | 100.0 ± 26.0 | 0.10 | 96.5 ± 26.0 | 107.2 ± 28.9 | 0.78 |
| Adjuvant treatment for ETP | ||||||
| TMZ + avastin | - | 13 | - | - | 1 | - |
| TMZ/avastin monotherapy | - | 6/8 | - | - | 8/4 | - |
| Others | - | 8 | - | - | 1 | - |
Note: Data are expressed as the mean ± standard deviation. Numbers in parentheses are percentage. Abbreviations: PP = pseudoprogression, NA = not available. Others include irinotecan monotherapy, vincristine monotherapy, or their combination with avastin.